Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

Cryotherapy 12 resiquimod 6 Cantharidin 5 PRA1 protein, Candida albicans 4 Tuberculin 3 Salicylic Acid 3 Cholecalciferol 3 plerixafor 2 VP-102 2 Solutions 2 Sodium Chloride 2 Saline Solution 2 Photochemotherapy 2 Percutaneous Collagen Induction 2 N-phenylacetoaminomethylene-DL-p-nitrophenylalanine 2 Measles-Mumps-Rubella Vaccine 2 Lasers 2 Hydrogen Peroxide 2 Human Papillomavirus Recombinant Vaccine nonavalent 2 3-ingenyl angelate 2 2-Propanol 2 methyl 5-aminolevulinate 1 leupin 1 lactic acid, salicylic acid drug combination 1 human papillomavirus vaccine, L1 type 16, 18 1 green tea extract polyphenone E 1 gluconic acid 1 ethyl pyruvate 1 compound W 1 ammonium trichloro(dioxoethylene-O,O'-)tellurate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Warts × ethyl pyruvate × Clear all

NCT01712295 2012-10-23

17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts

Grossman, Michael, D.P.M.

Phase 4 Unknown

Warts

Data powered by HemOnc (CC BY 4.0) Colophon ⚡